Kringle Pharma and Tripep AB, a Swedish biotechnology research company, reached to a basic agreement to co-develop recombinant human HGF (Hepatocyte Growth Factor) protein for wound healing therapy.

Kringle Pharma and Tripep AB, a Swedish biotechnology research company, reached to a basic agreement to co-develop recombinant human HGF (Hepatocyte Growth Factor) protein for wound healing therapy.